The opioid bowel syndrome: A review of pathophysiology and treatment
Abstract
Keywords
Full Text:
PDFReferences
Kurz A, Sessler DI: Opioid-induced bowel dysfunction: Pathophysiology and potential new therapies. Drugs. 2003; 63(7): 649-671.
DeLuca A, Coupar IM: Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996; 69(2): 103-115.
Tamayo AC, Diaz-Zuluaga PA: Management of opioidinduced bowel dysfunction in cancer patients. Support Care Cancer. 2004; 12: 613-618.
Bayguinov O, Sanders KM: Regulation of neural responses in the canine pyloric sphincter by opioids. Br J Pharmacol. 1993; 108(4): 1024-1030.
Hansen MB: The enteric nervous system II: Gastrointestinal functions. Pharmacol Toxicol. 2003; 92: 249-257.
Wood JD, Galligan JJ: Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004; 16(2): 17-28.
Hansen MB: The enteric nervous system III: A target for pharmacological treatment. Pharmacol Toxicol. 2003; 93: 1-13.
Choi YS, Billings JA: Opioid antagonists: A review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage. 2002; 24(1): 71-90.
Holzer P: Opioids and opioid receptors in the enteric nervous system: From a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett. 2004; 361: 192-195.
Hansen MB: Neurohumoral control of gastrointestinal motility. Physiol Res. 2003; 52: 1-30.
Bauer AJ, Boeckxstaens GE: Mechanisms of postoperative ileus. Neurogastroenterol Motil. 2004; 16 (Suppl 2): 54-60.
Sternini C, Patierno S, Selmer S, et al.: The opioid system in the gastrointestinal tract. Neurogastroenterol Motil. 2004; 16(2): 3-16.
Sternini C: Receptors and transmission in the brain-gut axis: Potential for Novel Therapies. III. Mu-opioid receptors in the enteric nervous system. Am J Physiol Gastrointest Liver Physiol. 2001; 281: G8-G15.
Holzer P: Opioids and opioid receptors in the enteric nervous system: From a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett. 2004; 361: 192-195.
Gue M, Junien JL, Bueno L: The kappa agonist fedotozine modulates colonic distention-induced inhibition of gastric motility and emptying in dogs. Gastroenterology. 1994; 107(5): 1327-1334.
Sanger GJ, Tuladhar BR: The role of endogenous opioids in the control of gastrointestinal motility: Predictions from in vitro modeling. Neurogastroenterol Motil. 2004; 16(2): 38-45.
Poonyachoti S, Portoghese PS, Brown DR: Characterization of opioid receptors modulating neurogenic contractions of circular muscle from procine ileum and evidence that delta- and kappa-opioid receptors are coexpressed in myenteric neurons. J Pharmacol Exp Ther. 2001; 297: 69-77.
Camilleri M: Alvimopan, a selective peripherally acting μ-opioid antagonist. Neurogastroenterol Motil. 2005; 17: 157-165.
Bitar KN, Makhlouf GM: Selective presence of opiate receptors on intestinal circular muscle cells. Life Sci. 1985; 37(16): 1545-1550.
De Schepper HU, Cremonini F, Park MI, et al.: Opioids and the gut: Pharmacology and current clinical experience. Neurogastroenterol Motil. 2004; 16: 383-394.
Johnson SM, Costa M, Humphreys CM: Opioid mu and kappa receptors on axons of cholinergic excitatory motor neurons supplying the circular muscle of guinea-pig ileum. Naunyn Schmiedebergs Arch Pharmacol. 1988; 338(4): 397-400.
Johnson SM, Costa M, Humphreys CM, et al.: Inhibitory effects of opioids in a circular muscle-myenteric plexus preparation of guinea-pig ileum. Naunyn Schmiedebergs Arch Pharmacol. 1987; 336(4): 419-424.
Grider JR, Makhlouf GM: Identification of opioid receptors on gastric muscle cells by selective receptor protection. Am J Physiol. 1991; 260(1 Pt 1): G103-G107.
Yuan, Chun-Su: Gastric effects of mu-, delta- and kappa-opioid receptor agonists on brainstem unitary responses in the neonatal rat. Eur J Pharmacol. 1996; 314: 27-32.
Zhang L, Gu ZF, Pradhan T, et al.: Characterization of opioid receptors on smooth muscle cells from guinea pig stomach. Am J Physiol. 1992; 262(3 Pt 1): G461-G469.
Greenwood-Van Meerveld B, Gardner CJ, Little PJ, et al.: Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil. 2004; 16 Suppl 2: 46-53.
Fox DA, Burks TF: Roles of central and peripheral mu, delta and kappa opioid receptors in the mediation of gastric acid secretory effects in the rat. J Pharmacol Exp Ther. 1988; 244(2): 456-462.
Bauer AJ, Szurszewski JH: Effect of opioid peptides on circular muscle of canine duodenum. J Physiol. 1991; 434: 409-422.
Nishiwaki H, Saitoh N, Nishio H, et al.: Relationship between inhibitory effect of endogenous opioid via mu-receptors and muscarinic autoinhibition in acetylcholine release from myenteric plexus of guinea pig ileum. Jpn J Pharmacol. 1998; 77(4): 279-286.
Kojima Y, Takahashi T, Fujina M, et al.: Inhibition of cholinergic transmission by opiates in ileal myenteric plexus is mediated by kappa receptor. Involvement of regulatory inhibitory G protein and calcium N-channels. J Pharmacol Exp Ther. 1994; 268(2): 965-970.
Bruera E, Brenneis C, Michaud M, et al.: Continuous Sc infusion of metoclopramide for treatment of narcotic bowel syndrome. Cancer Treat Rep. 1987; 71(11): 1121-1122.
Baig MK, Wexner SD: Postoperative ileus: A review. Dis Colon Rectum. 2004; 47: 516-526.
Taguchi A, Sharma N, Saleem RM, et al.: Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med. 2001; 345(13): 935-940.
Schmidt WK: Alvimopan (ADL8-2698) is a novel peripheral opioid antagonist. Am J Surg. 2001; 182(5A Suppl): 27S-38S.
Goodman M, Low J, Wilkinson S: Constipation management in palliative care: A survey of practices in the United Kingdom. J Pain Symptom Manage. 2005; 29(3): 238-244.
Sykes NP: The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med. 1998; 12: 375-382.
Lederle FA, Busch DL, Mattox KM, et al.: Cost-effective treatment of constipation in the elderly: A randomized double-blind comparison of sorbitol and lactulose. Am J Med. 1990; 89(5): 597-601.
Petticrew M, Watt I, Sheldon T: A systematic review of the effectiveness of laxatives in the elderly. Health Technol Assess. 1997; 1(13): 1-52.
Agra Y, Sacristan A, Gonzalez M, et al.: Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. J Pain Symptom Manage. 1998; 15(1): 1-7.
Attar A, Lemann M, Ferguson A, et al.: Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut. 1999; 44(2): 226-230.
Sykes NP: A volunteer model for the comparison of laxatives in opioid-related constipation. J Pain Symptom Manage. 1996; 11(6): 363-369.
Crowther AG: Management of constipation in terminally ill patients. J Int Med Res. 1978; 6(4): 348-350.
Ferguson A, Culbert P, Gillett H, et al.: New polyethylene glycol electrolyte solution for the treatment of constipation and faecal impaction. Ital J Gastroenterol Hepatol. 1999; 31 Suppl 3: S249-S252.
Freedman MD, Schwartz HJ, Roby R, et al.: Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: A doubleblinded placebo-controlled trial. J Clin Pharmacol. 1997; 37(10): 904-907.
Wong V, Sobala G, Losowsky M: A case of narcotic bowel syndrome successfully treated with clonidine. Postgrad Med J. 1994; 70(820): 138-140.
Daeninck PJ, Bruera E: Reduction in constipation and laxative requirements following opioid rotation to methadone: A report of four cases. J Pain Symptom Manage. 1999; 18(4): 303-309.
Cowan A: Buprenorphine: New pharmacological aspects. Int J Clin Pract Suppl 2003; 133: 3-8.
Joishy MD, Suresh K, Walsh D: The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: Application in bone metastases and the OBS. J Pain Symptom Manage. 1998; 16(5): 334-339.
Mercadante S, Fulfaro F, Casuccio A: A randomized controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: Effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer. 2002; 38(1): 1358-1363.
Radbruch L, Sabatowski R, Loick G, et al.: Constipation and the use of laxatives: A comparison between transdermal fentanyl and oral morphine. Palliat Med. 2000; 14(2): 111-119.
Allan L, Hays H, Jensen NH, et al.: Randomized crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ. 2001; 322(7295): 1154-1158.
Sykes NP: An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996; 10(2): 135-144.
Meissner W, Schmidt U, Hartmann M, et al.: Oral naloxone reverses opioid-associated constipation. Pain. 2000; 84: 105-109.
Liu M, Wittbrodt E: Low-dose oral naloxone reverses opioidinduced constipation and analgesia. J Pain Symptom Manage 2002; 23(1): 48-53.
Cheskin LJ, Chami TN, Johnson RE, et al.: Assessment of nalmephrene glucuronide as a selective gut opioid antagonist. Drug Alcohol Depend. 1995; 39: 151-154.
Yuan CS, Wei G, Foss JF, et al.: Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: A double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther. 2002; 300(1): 118-123.
Yuan CS, Foss JF: Antagonism of gastrointestinal opioid effects. Reg Anesth Pain Med. 2000; 25(6): 639-642.
Yuan CS, Foss JF, O’Connor M, et al.: Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: A pilot study. Pain. 1999; 83: 631-635.
Yuan CS, Foss JF, O’Connor M, et al.: Methylnaltrexone for reversal of constipation due to chronic methadone use: A randomized controlled trial. JAMA. 2000; 283(3): 367-372.
Yuan CS, Foss JF: Oral methylnaltrexone for opioid-induced constipation. JAMA. 2000; 284(11): 1383-1384.
Foss JF, O’Connor MF, Yuan CS, et al.: Safety and tolerance of methylnaltrexone in healthy humans: A randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. J Clin Pharmacol. 1997; 37(1): 25-30.
Foss JF: A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg. 2001; 182(5A Suppl): 19S-26S.
Barr WH, Nguyen P, Slattery M, et al.: ADL 8-2698 reverses opioid induced delay in colonic transit. Clin Pharmacol Ther. 2000; 67: 91.
Callaghan JT, Cerimele B, Nowak TV, et al.: Effect of the opioid antagonist LY246736 on gastrointestinal transit in human subjects. Gastroenterology. 1998; 114: G3015.
Liu SS, Hodgson PS, Carpenter RL, et al.: ADL 8-2698 a trans 3, 4 dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther. 2001; 69: 66-71.
Paulson DM, Kennedy DT, Donovick RA, et al.: Alvimopan: An oral, peripherally acting, μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction—a 21 day treatment randomized clinical trial. J Pain. 2005; 6(3): 184-192.
Wolff BG, Michelassi F, Gerkin TM, et al.: Alvimopan, a novel, peripherally acting mu opioid antagonist: Results of a multicentre, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg. 2004; 240(4): 728-734.
DOI: https://doi.org/10.5055/jom.2005.0035
Refbacks
- There are currently no refbacks.